Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morino, S.
Right arrow Articles by Shimizu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morino, S.
Right arrow Articles by Shimizu, Y.
(Chest. 2005;128:920-926.)
© 2005 American College of Chest Physicians

Fibroblast Growth Factor-2 Induces Recovery of Pulmonary Blood Flow in Canine Emphysema Models*

Shigeyuki Morino, MD; Tatsuo Nakamura, MD; Toshinari Toba, MD; Mitsuru Takahashi, MD; Toshihiro Kushibiki, MD; Yasuhiko Tabata, MD and Yasuhiko Shimizu, MD

* From the Institute for Frontier Medical Sciences (Drs. Nakamura, Toba, Takahashi, Kushibiki, Tabata, and Shimizu), Kyoto University, Kyoto; and Division of Surgical Oncology (Dr. Morino), Nagasaki University School of Medicine, Nagasaki, Japan.

Correspondence to: Shigeyuki Morino, MD, Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; e-mail: morinos{at}frontier.kyoto-u.ac.jp


   Abstract
TOP
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Study objectives: Fibroblast growth factor (FGF)-2 is one of the most powerful angiogenic growth factors to be evaluated as an agent for the promotion of angiogenesis. The aim of this study is to investigate whether intratracheal administration of controlled-release FGF-2 microspheres restores pulmonary function in beagle dogs with emphysema.

Design: Randomized, controlled, experimental animal study.

Subjects: Eighteen Wister rats and 15 adult beagle dogs.

Methods: In the rat study, we compared the time profiles of the radioactivity remaining after intratracheal injection of 125I-labeled FGF-2, either incorporated with the controlled-release microspheres or as an aqueous solution. In the dog study, elastase-induced emphysema models were developed in 10 animals, classified into the following three groups: control group (n = 5), emphysema model with empty microspheres-treated group (FGF – group, n = 5), and emphysema model with FGF-2 containing microspheres-treated group (FGF + group, n = 5).

Results: In the rat study, controlled-release microspheres maintained higher whole-lung FGF-2 concentrations after intratracheal administration. In the dog study, PaO2 in the FGF + group was significantly higher than in the FGF – group after treatment. Pulmonary perfusion dynamic MRI revealed significant improvement in the signal intensity of damaged lung with the FGF + group. Linear intercept of the FGF + group was significantly reduced than the FGF – group.

Conclusion: Results indicate that intratracheal administration of FGF-2 induced an increase in pulmonary blood flow in the damaged lung and led to recovery of pulmonary function. The controlled-release microsphere system increased the effectiveness of FGF-2.

Key Words: angiogenesis • COPD • emphysema • fibroblast growth factor • regeneration


   Introduction
TOP
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Lung volume reduction surgery (LVRS) improves lung function, exercise capacity, and quality of life in patients with advanced emphysema by allowing the remaining pulmonary parenchyma and the respiratory muscles to function more effectively. Although the physiologic and symptomatic benefits of LVRS have, on average, been impressive, the substantial rates of morbidity and mortality associated with major thoracic surgery and general anesthesia in an elderly, debilitated population have limited the clinical utility of the procedure. Moreover, patients with the most advanced disease have higher surgical mortality, suggesting that LVRS is not suitable for those with severe disease.12 There is currently no therapy for the treatment of lung emphysema. Noninvasive treatment is desirable for severe emphysema patients.

Fibroblast growth factor (FGF)-2 is one of the most powerful angiogenic growth factors to be evaluated as an agent for the promotion of angiogenesis. Patients with severe emphysema have higher-than-normal pulmonary arterial pressure. Severe emphysema also tends to produce diffuse microvessel abnormalities in the pulmonary peripheral arteries.3 Induction of a collateral pulmonary vessel network is a potent method of providing effective relief from dyspnea, general fatigue, and other symptoms in emphysema. Polymer hydrogels composed of gelatin have previously been demonstrated to be suitable matrices for the controlled release of growth factors because of their biosafety and the fact that they are highly inert toward protein drugs.4 Biodegradable gelatin microspheres incorporating FGF-2 have been developed using acidic gelatin hydrogels. The use of these microspheres enables FGF-2 to be released at the site of action over a sufficiently long period of time to act effectively, in remarkable contrast to free FGF-2.5 The aim of the present study was to investigate whether there is a benefit of bronchoscopic administration of FGF-2 on elastase-induced emphysema animals.


   Materials and Methods
TOP
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Distribution of FGF-2 Intratracheal Administration in Rats
Eighteen female Wister rats weighing 250 to 300 g and 15 adult beagle dogs weighing 10.0 to 14.9 kg were used in this study. The study protocol was approved by the Kyoto University Ethics Committee for Animal Research. All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press.

The rats were anesthetized with pentobarbital sodium, and the trachea was exposed. All the FGF-2 was labeled by 125I. 125I-labeled FGF-2 was injected via 0.3 mL of solution to the trachea (FGF solution group, n = 9). 125I-labeled–FGF-2 microspheres were injected in 0.3 mL of suspended solution to the trachea (FGF microsphere group, n = 9). Lung tissues were obtained at different time intervals: 24 h, 72 h, and 7 days. The radioactivity remaining was calculated from the whole lung on a gamma counter (ARC-301B; Aloka; Tokyo, Japan).

Preparation of the Elastase-Induced Emphysema Model
The 15 beagle dogs were classified at random into the following three groups: control group, emphysema model with empty microspheres-treated group (FGF – group), and emphysema model with FGF-2 containing microspheres-treated group (FGF +) group. Models of elastase-induced emphysema were developed in the FGF – and FGF + groups. All interventions and physiologic measurements were performed under general anesthesia with ketamine hydrochloride (10 mg/kg) and xylazine (30 mg/kg), and mechanical ventilation was administered through an endotracheal tube. A 9.0-mm diameter endotracheal tube was inserted into the trachea under bronchoscopic guidance and attached to a mechanical ventilator. Continuous monitoring included ECG, oxygen saturation by reflectance oximetry using a sensor clipped to the ear, and body temperature by means of a rectal probe. A bronchoscope (5 mm outside diameter and 60 cm working length) was introduced through the indwelling endotracheal tube and advanced to the left segmental bronchus. Then, 40 mg (3,000 U) of porcine pancreatic elastase (Nakarai Tesque; Kyoto, Japan) was dissolved in 5 mL of saline solution and sprayed into all segmental bronchi of the left lung through the instrument channel of the bronchoscope using a spray infusion catheter (Olympus Optical; Tokyo, Japan) in the elastase-induced emphysema models. Each elastase dose was divided into 10 portions, each of which was sprayed in a different area to make a model of diffuse emphysema at the level of the left segmental bronchus. The right lung was preserved intact as a control.

Arterial Blood Gas and Pressure/Volume Relationships
Assessment of pulmonary function and MRI were performed before elastase administration (baseline), 4 weeks after elastase administration, and 4 weeks after treatment. For assessment of pulmonary function, dogs were anesthetized, intubated, and maintained on < 3.0% halothane. Arterial blood pH, PaCO2, PaO2, and percentage of oxygen saturation were measured. Mechanical ventilation was set at a breathing frequency of 10 breaths/min, the inspiratory time was set to 33% of the breathing period, and the fraction of inspired oxygen was 0.2. Tidal volume was set to 18 mL/kg. Arterial blood gas samples were obtained from the right femoral artery 15 min after mechanical ventilation was started. A blood gas and acid-base analyzer (ABL-620; Radiometer; Copenhagen, Denmark) was used for measurements. Pressure/volume (P/V) relationships and expiratory capacity were also measured under general anesthesia with intubation. The intratracheal cavity was inflated to various pressures (5 to 70 cm H2O), and the endotracheal tube was then clamped tightly. A plethysmograph (HI-701; Nihon Kohden; Tokyo, Japan) was connected to the endotracheal tube and the clamp was released, and then the expiratory capacity was measured. The expiratory capacity when the intratracheal cavity was inflated to a pressure of 40 cm H2O (expiratory capacity, 40 cm H2O) was used for calculations.

Dynamic Contrast-Enhanced MRI
All MRI studies were performed (1.5 T Sonata; Siemens Medical Systems; Erlangen, Germany) with a maximum amplitude of 40 mT/m and a rise time of 0.6 ms, using a phased-array body coil with four active segments. A turbo fast low-angle shot sequence optimized for projection imaging was used for dynamic contrast-enhanced MRI.6 The following image parameters were used: echo time/repetition time, 1.35/350 ms; flip angle, 8°; readout bandwidth, 500 Hz/pixel; section thickness, 20 mm; field of view, 300 to 350 x 140 to 170 mm; image matrix, 110 x 256; and voxel size, 1.3 x 1.2 x 20.0 mm3. For the MRI scan, each dog was anesthetized and a 16-gauge IV catheter was introduced into the right internal jugular vein. The dog was then fixed in a supine position and 3 mL of gadopentetate dimeglumine (Magnevist; Nihon Schering; Osaka, Japan) was administered as an IV bolus over 1 s. The contrast agent was administered immediately after the start of the dynamic imaging procedure. A total of 170 axial images were acquired to provide consecutive measurements over the 60-s scan time. The image immediately before the image showing any vascular enhancement was utilized as a mask image for subsequent image subtraction. For the imaging procedure, the signal intensity curves were measured from the right and left lung parenchymal areas (plotting area) separately. The mean signal intensity was calculated from the signal intensity curve during the 60-s scan time. The flow-volume ratio was calculated from the mean signal intensity of the left lung to the right lung, according to the following equation:

Administration of FGF-2 Microspheres
Human recombinant FGF-2 was supplied by Kaken Pharmaceutical Company, Tokyo, Japan. Gelatin was isolated from bovine bone collagen by an alkaline process using CaOH2 (Nitta Gelatin Company; Osaka, Japan). FGF-2 microspheres with a diameter of approximately 10 µm were prepared as described previously by glutaraldehyde cross-linking of gelatin.45 After washing with acetone (4°C), the microspheres were recovered by centrifugation. FGF-2 was radioiodinated and incorporated into the microspheres over a 1-h period before use. In the FGF + group, a total of 200 µg of FGF-2 was incorporated into each 4.0 mg of gelatin hydrogel microspheres. After performing a bronchoscopic examination, 4.0 mg of FGF-2 microspheres were suspended in 5 mL of saline solution and sprayed into the emphysematous left lung using a spray infusion catheter in 10 divided doses in a different area. The FGF – group were sprayed with 4.0 mg of gelatin hydrogel microspheres without FGF-2 using the same procedure into the left lung.

Histologic Measurement
Four weeks after treatment, the dogs in each group were euthanized by injection of pentobarbital sodium. The lung tissues and heart, along with the trachea, were resected en bloc. The heart and mediastinal tissues were removed, and the lungs with the attached trachea were weighed. The lungs were immediately inflated with 10% neutral buffered formalin solution via a tracheal cannula at a pressure of 25 cm H2O until the pleura became tense. The trachea was then ligated, and the lungs were fixed further by immersion in formalin solution for 48 h. The inflated lung volume was measured by the water replacement method, and the left and right lungs were measured separately.7 Twenty 2 x 2x2-cm blocks were randomly cut from the whole area of the lung per animal. The blocks were then embedded in paraffin before being cut into 3-µm-thick sections and stained with hematoxylin-eosin. All the sections were used to measure mean linear intercept (Lm), a commonly used stereologic indicator of alveolar airspace enlargement in emphysema, which was calculated as described.8 Sixty fields per animal at 40 x magnification were chosen at random to measure Lm.

Statistical Analysis
Data are expressed as mean (SD). Data were analyzed by analysis of variance using statistical software (StatView for Windows, version 5.0; SAS Institute; Cary, NC). Differences between groups were identified by a Scheffe test; p values < 0.05 were considered statistically significant.


   Results
TOP
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Distribution of FGF-2 Intratracheal Administration in the Rat
Figure 1 shows a summary of the FGF-2 remaining after intratracheal administration in the rats. Radioactivity remaining after intratracheal administration decreased with time. In the FGF solution group, radioactivity count remaining at 24 h, 72 h, and 7 days was 35.4 ± 3.6, 5.4 ± 2.5, and 1.2 ± 0.17, respectively. In the FGF microsphere group, remaining levels of FGF-2 were significantly higher than in the FGF solution group (p = 0.003). Radioactivity remaining at 24 h, 72 h, and 7 days was 50.2 ± 10.5, 13.7 ± 1.6, and 2.9 ± 1.63, respectively. These results suggest that the controlled-release microsphere system increased the effectiveness of FGF-2.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1.. In vivo time profile of radioactivity remaining after intratracheal injection of gelatin microspheres incorporating 125I-labeled–FGF-2 (microsphere) or intratracheal injection of 125I-labeled–FGF-2 in aqueous solution (solution) into the rat trachea. In the FGF microsphere group, remaining levels of radioactivity were significantly higher than in the FGF solution group (p < 0.01). Data are presented as mean ± SD from nine rats per group at different time intervals: 24 h, 72 h, and 7 days.

 
Pulmonary Function Tests in the Canine Experiment
Body weights did not differ between the FGF – group and the FGF + group: 11.4 ± 1.3 kg vs 11.8 ± 1.9 kg, respectively. There were no differences in body weight 4 weeks after elastase administration and 4 weeks after treatment (FGF – group, 11.6 ± 1.2 kg vs 11.5 ± 1.5 kg; FGF + group, 11.5 ± 2.1 kg vs 11.0 ± 2.3 kg). There was no evidence of serious side effects, including thrombocytopenia, anemia, or renal dysfunction, after FGF-2 administration.

Data for PaO2 are shown in Figure 2 , top, A. There were no differences in any parameters between the two groups at baseline and 4 weeks after elastase administration: FGF –, 95.5 ± 7.3 mm Hg vs 85.5 ± 3.0 mm Hg; FGF +, 92.8 ± 4.2 mm Hg vs 88.7 ± 3.4 mm Hg, respectively. Elastase-induced emphysema models had significantly lower PaO2 values at 4 weeks after elastase administration than at the baseline (p = 0.015). Four weeks after treatment, PaO2 in the FGF + group was significantly higher than in the FGF – group: 83.7 ± 4.6 mm Hg vs 95.3 ± 5.9 mm Hg (p = 0.036).



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2.. Results of pulmonary function tests in the FGF – group and the FGF + group. Top, A: Changes in PaO2. Elastase-induced emphysema models had significantly lower PaO2 values at 4 weeks after elastase administration than at baseline (p = 0.015). PaO2 in the FGF + group was significantly higher than in the FGF – group at 4 weeks after treatment (p = 0.036). Bottom, B: The P/V relationship. The intratracheal cavity was inflated at different pressures (5 to 70 cm H2O). Elastase-induced = elastase-induced emphysema models. The curve in the FGF – group was shifted upward to a greater extent than in the elastase-induced emphysema, whereas that in the FGF + group was shifted downward. N.S. = not significant.

 
The intratracheal cavity was inflated at different pressures (5 to 70 cm H2O). In the elastase-induced emphysema models, the P/V curve was shifted upward compared with the baseline. The curve in the FGF – group continued to shift upward, whereas that in the FGF + group shifted downward (Fig 2, bottom, B). The FGF + group appeared to exhibit better recovery than the FGF – group in terms of expiratory capacity with intratracheal pressure of 40 cm H2O (0.88 ± 0.20 L vs 0.79 ± 0.18 L), although the difference was not statistically significant (p = 0.72). These results suggested pulmonary functional recovery in the FGF + group.

Dynamic Contrast-Enhanced MRI
MRI scans of pulmonary perfusion allowed the bolus of contrast agent to be followed through the superior vena cava, right atrium and ventricle, pulmonary arteries, lung parenchyma, pulmonary veins, left heart, and systemic arteries. At 5 s, the pulmonary arterial tree could be visualized beyond the segmental branches. A diffuse flash on the lung parenchyma was then observed, followed by a gradual increase in signal intensity over the next 20 s (Fig 3 ). In the elastase-induced emphysema models, the signal intensity was visually lower in the left lung. The left signal intensity was improved in the FGF + group. The difference between the left and right signals was maximal at 20 s. The signal intensity curves during the 60-s scan time are demonstrated in Figure 4 . At the baseline, the levels of the signal intensity curves were the same in the right and left lungs. The signal intensity curve in the elastase-induced emphysema models declined in the left lung compared with the right (Fig 4, top right, B), and the signal intensity curve showed a sharply marked first-pass effect of enhancement with a significant lower-intensity peak on the pathologic side. The signal intensity curve in the FGF + group improved significantly in the left lung (Fig 4, bottom right, C). The flow-volume ratios at baseline were 0.99 ± 0.02 and 1.00 ± 0.04 in the FGF – group and the FGF + group, respectively (Fig 5 ). Four weeks after elastase administration, the flow-volume ratio was significantly lower than baseline: FGF – group, 0.70 ± 0.06; FGF + group, 0.69 ± 0.07. Four weeks after treatment, dynamic MRI revealed significant improvement in the FGF + group. The flow-volume ratio in the FGF + group was significantly improved after FGF-2 treatment, while the FGF – group score was the same as, or worse than, that in the dogs assessed before treatment: FGF –, 0.69 ± 0.05; FGF +, 0.88 ± 0.06 (p = 0.0041).



View larger version (99K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3.. Dynamic contrast-enhanced MRI at baseline (top row, A), elastase-induced elastase-induced emphysema models (upper center row, B), the FGF – group (lower center row, C), and FGF + group (bottom row, D). At 5 s, the pulmonary arterial tree could be visualized beyond the segmental branches, followed by a gradual increase of signal intensity over the next 20 s. In the elastase-induced emphysema models, the signal intensity in the left lung was visually lower than that in the right lung. In the FGF + group, the signal intensity improved in the left lung, while the FGF – group showed no change.

 


View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4.. Signal intensity curves for the lung parenchyma (plotting area) after administration of gadopentetate dimeglumine during a 60-s scan time. Left, A: Baseline. The signal intensity curves for the left (Lt) and right (Rt) lungs were similar. Top right, B: Elastase-induced emphysema models. The signal intensity curve declined in the left lung compared with the right, and showed a sharply marked first-pass effect of enhancement with a significantly lower-intensity peak. Bottom right, C: FGF + group. Signal intensity curve was improved in the left lung.

 


View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5.. Flow-volume ratio determined by dynamic contrast-enhanced MRI. Four weeks after elastase administration, the flow-volume ratio was significantly lower than at baseline. The flow-volume ratio in the FGF + group was significantly improved after FGF-2 treatment, while the score for the FGF – group was the same as or worse than that for the dogs assessed before treatment. See Figure 2 legend for expansion of abbreviation.

 
Lung Volumes and Histologic Findings
A summary of the effects of FGF-2 on lung volume throughout the study period is presented in Figure 6 . In the animals of the FGF – group, the left lung was overinflated compared with the control group. There were no changes in right lung volumes among the three groups. The left lung volume in the FGF + group was reduced compared to the FGF – group, although the difference was not statistically significant: control, 380.0 ± 82.9 cm3; FGF –, 442.9 ± 50.4 cm3; FGF +, 402.8 ± 71.8 cm3. At autopsy, the tissue destruction caused by the elastase was associated with physiologic changes and a marked reduction in the surface area available for gas exchange (Fig 7 ). In the FGF + group, the mean size of alveoli was closer to control group than that of the FGF – group. There were no significant differences in right lung Lm levels among the three groups. Left lungs that had received elastase had a significantly increased Lm compared with the control group: control, 52.3 ± 2.8 µm; FGF –, 71.6 ± 4.0 µm; FGF +, 63.5 ± 3.2 µm. Lm levels in the control group and the FGF – group were significantly different (p < 0.001). The Lm value for the FGF + group appeared to indicate better recovery than in the FGF – group (p = 0.02).



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6.. Histologic findings. Left, A: Lung volumes. Right, B: Linear intercept values. Left lung volumes in the FGF + group were reduced in comparison with the FGF – group. Left lungs that had received elastase showed significantly increased Lm values compared with those in the control group. *Lm levels in the control group and the FGF – group were significantly different from each other (p < 0.001). **The Lm value for the FGF + group appeared to indicate better recovery than in the FGF – group (p = 0.02). Rt lung = intact lung; Lt lung = treated lung.

 


View larger version (110K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 7.. Representative photomicrographs of hematoxylin-eosin–stained sections (original x 40). Left, A: Control group; top right, B: FGF – group; and bottom right, C: FGF + group. The tissue destruction caused by the elastase was associated with physiologic changes and a marked reduction in the surface area. In the FGF + group, the mean size of alveoli was closer to the control group than that of the FGF – group.

 

   Discussion
TOP
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Growth factors and biological regulators have been evaluated experimentally with respect to their potential usefulness in promoting pulmonary parenchymal regeneration in emphysema.91011 Reports1114 have suggested that growth factors play an important role in fetal lung development in both rodents and humans. FGF is a member of the heparin-binding polypeptide family. It is widely distributed and has been identified in many tissues of neuroectodermal and mesodermal origin. FGF acts as an angiogenic molecule in vitro, while in vivo it stimulates smooth muscle cell growth, wound healing, and tissue repair.12 FGF-2 is one of the most powerful angiogenic factors known and is indispensable for lung development and branching morphogenesis. Studies1314 of the expression of FGF-2 and receptors in the developing fetal rat lung have shown that FGF-2 immunoreactivity is localized to cells of the airway epithelium, basement membranes, and extracellular matrix. However, although these characteristics of FGF-2 indicate that it would be a potent promoter of pulmonary functional recovery in emphysema, its biological half-life is reported to be < 50 min, which is too short a time to maintain a sustained response. In addition, endothelial cells take almost 1 day to begin to respond to FGF-2 stimulation.1516 Hence, the simple administration of free FGF-2 results in few of the desired biological activities such as angiogenesis, branching morphogenesis, and pulmonary functional regeneration. In fact, some researchers17 have reported that FGF-2 administration produces insufficient angiogenesis to induce revascularization and subsequent airway healing. We used controlled-release microspheres as vehicles for more effective induction of angiogenesis by FGF-2.

When preparing microspheres, FGF-2 is incorporated into the hydrogel mainly as a result of physicochemical and electrical interactions between FGF-2 and the acidic gelatin, similar to the processes observed during hydrogen bonding and hydrophobic interactions.4 Once incorporated, it is likely that the FGF-2 will be released from the gelatin hydrogel only when the hydrogel is enzymatically degraded to water-soluble gelatin fragments in vivo. A potential problem with this delivery system is therefore that FGF-2 release can only be controlled by changing the in vivo degradability of the gelatin hydrogels. This can be achieved by manipulating the water content of the hydrogels during their preparation.45 We considered whether the microspheres could function as a drug delivery system in the airway and whether they had any unexpected side effects in the lung. In this in vivo study in rats, we compared the time profiles of the radioactivity remaining after intratracheal administration of 125I-labeled–FGF-2 either incorporated with an acidic gelatin hydrogel or as an aqueous solution. The gelatin hydrogel yielded a higher radioactivity count than the aqueous solution, thus confirming the effectiveness of the gel as a controlled-release mechanism. The controlled-release microspheres expanded the effects of FGF-2 and prolonged its biological half-life in vivo. There was no evidence of serious complications including infection, atelectasis, allergy, and hemorrhage after gelatin hydrogels microspheres administration in this study. However, IV injection of hydrogels has a risk of vascular infarction. Therefore, gelatin microspheres cannot administer by the IV route.

Many groups have researched the lung parenchymal regeneration and alveolar septation for the chronic obstructive pulmonary diseases.91118 The mechanisms underlying regeneration and alveolar septation in the respiratory organs are still unclear, and it was not possible to determine whether FGF-2 treatment induced an increase in the number of alveoli or in alveolar septation. To date, we have found that FGF-2 treatment for COPD improves pulmonary function in the beagle dogs. The improvement in arterial oxygen gas data can be explained by the following: FGF-2 treatment led to a volume reduction in the affected lung and improvement of blood flow; subsequently, alveolar gas pressure also improved. Because oxygen uptake into the blood is dependent on the presence of a difference between the alveolar and capillary oxygen pressures, these improvements led to an improvement in the ventilation/perfusion shunt and in the gas exchange ability of the lung. In fact, little hypoxemia was observed after FGF-2 treatment, and the respiratory performance status of all dogs was improved, with no evidence of respiratory insufficiency.

There are some difficulties in attempting to achieve parenchymal regeneration and alveolar septation by the introduction of FGF-2 alone, because in the extracellular environment many growth factors and biological regulators interact with each other to produce parenchymal regeneration or alveolar septation.1319 It is difficult for tissue regeneration to occur in regions where blood flow is poor: pulmonary blood flow recovery is indispensable for lung regeneration and wound healing. Our present results indicate that the powerful angiogenic effect of FGF-2 induced both pulmonary revascularization and pulmonary vasodilation in the canine emphysema models, and suggest that this treatment may improve the symptoms of emphysema in humans. The magnitude of the physiologic improvement seen in response to FGF-2 treatment in this experimental model would be expected to benefit patients with severe emphysema to combine the intratracheal FGF-2 treatment and LVRS. We believe that intratracheal FGF-2 treatment has effective potential for emphysema, and that it will become one of the standard therapies for severe emphysema patients.

In conclusion, intratracheal administration of FGF-2 induced an increase in pulmonary blood flow in the damaged lung and volume reduction in the emphysematous lung. These changes led to an improvement in the ventilation/perfusion shunt and thus introduced the pulmonary functional recovery. The use of a controlled-release microsphere delivery system increased the effectiveness of FGF-2.


   Footnotes
 
Abbreviations: FGF = fibroblast growth factor; FGF – group = emphysema model with empty microspheres-treated group; FGF + group = emphysema model with FGF-2 containing microspheres-treated group; Lm = mean linear intercept; P/V = pressure/volume; LVRS = lung volume reduction surgery

FGF-2 was provided by Kaken Pharmaceutical Company, Tokyo, Japan; and gadopentetate dimeglumine was provided by Magnevist, Nihon Schering, Osaka, Japan.

Received for publication September 2, 2004. Accepted for publication January 3, 2005.


   References
TOP
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. . National Emphysema Treatment Trial Research Group. (2003) A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348,2059-2073[Abstract/Free Full Text]
  2. National Emphysema Treatment Trial Research Group.. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003;348,2092-2102[Abstract/Free Full Text]
  3. Doi, M, Nakano, K, Hiramoto, T, et al Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxia. Respir Med 2003;97,915-920[CrossRef][ISI][Medline]
  4. Tabata, Y, Hijikata, Y, Muniruzzaman, MD, et al Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polymer Edn 1999;10,79-94
  5. Yamamoto, M, Ikada, Y, Tabata, Y Controlled release of growth factors based on biodegradation of gelatin hydrogel. J Biomater Sci Polymer Edn 2001;12,77-88
  6. Hatabu, H, Tadamura, E, Levin, DL, et al Quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI. Magn Reson Med 1999;42,1033-1038[CrossRef][ISI][Medline]
  7. Scherle, W A simple method for volumetry of organs in quantitative stereology. Mikroskopie 1970;26,S57-60
  8. Gillooly, M, Lamb, D, Farrow, ASJ New automated technique for assessing emphysema on histological sections. J Clin Pathol 1991;44,1007-1011[Abstract/Free Full Text]
  9. Massaro, GD, Massaro, D Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3,675-677[CrossRef][ISI][Medline]
  10. Krause, DS, Theise, ND, Collector, MI, et al Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105,369-377[CrossRef][ISI][Medline]
  11. Selman, M, Cisneros-Lira, J, Gaxiola, M, et al Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003;123,1633-1641[Abstract/Free Full Text]
  12. Bikfalvi, A, Klein, S, Pintucci, G, et al Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18,26-45[Abstract/Free Full Text]
  13. Chabut, D, Fischer, AM, Colliec-Jouault, S, et al Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent {alpha}6 overexpression. Mol Pharmacol 2003;64,696-702[Abstract/Free Full Text]
  14. Ambalavanan, N, Novak, ZE Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates. Pediatr Res 2003;53,240-244[CrossRef][ISI][Medline]
  15. Lazarous, DF, Schinowitz, M, Shou, M, et al Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91,145-153[Abstract/Free Full Text]
  16. Schaper, W, De Brabander, M, Lewi, P DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res 1971;28,671-679[Abstract/Free Full Text]
  17. Behrend, M, von Wasielewski, R, Klempnauer, J Failure of airway healing in an ovine autotransplantation model that includes basic fibroblast growth factor. J Thorac Cardiovasc Surg 2002;124,231-240[Abstract/Free Full Text]
  18. Lucey, EC, Goldstein, RH, Breuer, R, et al Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema. Respiration 2003;70,200-205[CrossRef][ISI][Medline]
  19. Pepper, MS, Vassalli, JD, Orci, L, et al Biphasic effect of transforming growth factor ß1 on in vitro angiogenesis. Exp Cell Res 1993;204,356-363[CrossRef][ISI][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morino, S.
Right arrow Articles by Shimizu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morino, S.
Right arrow Articles by Shimizu, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS